Document Detail


Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis.
MedLine Citation:
PMID:  9635620     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We postulated that coadministration of cholylsarcosine with ursodeoxycholic acid might provide additional benefit to primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid. Our aim was to test the tolerability and the effect of adjuvant cholylsarcosine on liver tests and plasma cholesterol in primary biliary cirrhosis patients receiving ursodeoxycholic acid. Four primary biliary cirrhosis patients, who, despite more than a year of ursodeoxycholic acid therapy, had one or more liver tests persistently equal to or greater than twice the upper limit of normal, received cholylsarcosine (12-15 mg/kg/day) in addition to ursodeoxycholic acid (13-15 mg/kg/day) for six weeks in an open label study. Values of liver tests and plasma cholesterol, determined every two weeks, remained unchanged. One patient discontinued cholylsarcosine at week 4 because of new-onset pruritus. Analysis of duodenal bile acids in one patient showed 52% enrichment in cholylsarcosine and hydrophilic bile acids constituted 87% of total bile acids. It is concluded that the addition of cholylsarcosine to ursodeoxycholic acid did not influence liver tests in four primary biliary cirrhosis patients who had not responded completely to ursodeoxycholic acid alone. Cholylsarcosine was absorbed and became a dominant biliary bile acid; its administration was associated with increased pruritus.
Authors:
P Ricci; A F Hofmann; L R Hagey; R A Jorgensen; E Rolland Dickson; K D Lindor
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Digestive diseases and sciences     Volume:  43     ISSN:  0163-2116     ISO Abbreviation:  Dig. Dis. Sci.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-07-01     Completed Date:  1998-07-01     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7902782     Medline TA:  Dig Dis Sci     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1292-5     Citation Subset:  AIM; IM    
Affiliation:
Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cholagogues and Choleretics / therapeutic use*
Cholesterol / blood
Cholic Acids / therapeutic use*
Drug Therapy, Combination
Female
Humans
Liver Cirrhosis, Biliary / blood,  drug therapy*,  physiopathology
Liver Function Tests
Male
Middle Aged
Sarcosine / analogs & derivatives*,  therapeutic use
Ursodeoxycholic Acid / therapeutic use*
Grant Support
ID/Acronym/Agency:
DK 21506/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Cholagogues and Choleretics; 0/Cholic Acids; 107-97-1/Sarcosine; 128-13-2/Ursodeoxycholic Acid; 57-88-5/Cholesterol; 93790-70-6/cholylsarcosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Gallstone prevalence in Germany: the Ulm Gallbladder Stone Study.
Next Document:  Esophageal varices in rat models of liver cirrhosis.